Results 101 to 110 of about 57,115 (246)

Irinotecan in combination with new agents [PDF]

, 2004
Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with
JL Van Laethem, U. Vanhofer, Sobrero, Alberto, A. Munoz, Borner, M, Van Laethem, Jean-Luc, Muñoz, A., Borner, Markus, Rougier, Philippe, P. Rougier, M. Borner, Vanhoefer, U, Van Laethem, J.-L, Vanhoefer, Udo, Rougier, P, Muñoz, A, Sobrero, A   +16 more
core   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Cancer Treatment and Research Communications
Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff   +13 more
doaj   +1 more source

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

, 2017
Masashi Takano1 Toru Sugiyama2 1Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 2Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan Abstract: Mutations in the UGT1A1 ...
Takano M, Sugiyama T
core  

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Irinotecan or FOLFIRI for 2nd line colorectal [PDF]

, 2011
Background Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5- fluorouracil or alone in patients previously treated with a ...
Ransom, David T, Gebski, Val, Yip, Sonia, Tebbutt, Niall C, Buck, Martin, Simes, R John, Boland, Amy, Clarke, Stephen, Zalcberg, John, Brown, Chris, Van Hazel, Guy, Lowenthal, Raymond M, Jeffrey, G Mark, Goldstein, David   +13 more
core  

Genotype‐Informed Whole‐Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC

Cancer Science, EarlyView.
Overview of experimental workflow and key findings. Clinically prevalent 2‐hit and 3‐hit PDAC genotypes were first modeled in Drosophila to enable kinome‐wide genetic screening. Candidate therapeutic targets were prioritized using human tumor expression data and pathway enrichment analyses.
Han Hai, Takako Ooshio, Hui Jiang, Taku Kimura, Yusuke Satoh, Soichiro Hata, Taiga Hirata, Jiayi Liu, Tongwei Liu, Ryodai Yamamura, Masahiro Sonoshita   +10 more
wiley   +1 more source

Rifaximin alleviates irinotecan-induced diarrhea in mice model

Annals of Medicine
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang, Huiyin Lan, Minghua Bai, Jinggang Chen, Shengkun Xu, Quanquan Sun, Qianping Chen, Wei Mao, Jin Jiang, Ji Zhu   +9 more
doaj   +1 more source

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

, 2001
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic
Wolf Achterrath, Udo Vanhoefer, Andreas Harstrick, Siegfried Seeber, Shousong Cao, Youcef M. Rustum   +5 more
core   +1 more source

Eruptive Acral Melanocytic Lesions Associated With Capecitabine

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Eruptive nevi and lentigines have been reported to occur in the setting of immunosuppression, which may be medication‐induced. The associated histopathologic findings have not been well described in the literature. Herein, we report the case of a woman in her 60s who had been receiving chemotherapy treatment with capecitabine, a prodrug of 5 ...
Madison Smith, Annie Jin, Jonathan A. Miles, Rosalie Elenitsas, Danielle M. DeHoratius, Emily Y. Chu   +5 more
wiley   +1 more source